"Significant upside from NSAID pain program - Imugene currently have Phase I clinical data for naproxen (branded in Australia as Naprosyn) and ibuprofen (branded in Australia as Nurofen) and are initiating formulation development for diclofenac (branded in Australian as Voltaren). If successful, even a small share of the NSAID market (<0.5%) would represent an opportunity of $50M-$100M in annual sales (assume single digit royalties to Imugene)."
$50-100M?? that's 20-50 baggers potential!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
-0.045(10.6%) |
Mkt cap ! $83.46M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.0¢ | 34.5¢ | $1.196M | 3.248M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2058 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 53026 | 3 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |